SCHEMBL7708056

SCHEMBL7708056

CC1Oc2ccc(CN(Cc3ccccc3Cl)C(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 8/20 0.47
HSD17B10 Q99714 2/20 0.40
ALOX15 P16050 1/20 0.40
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
SMYD3 Q9H7B4 1/20 0.36
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
KDR P35968 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708215 0.91 PARP1 (0.42) PARP1HSD17B10ALOX15ALDH1A1USP2
SCHEMBL7711006 0.90 PARP1 (0.36) PARP1HSD17B10ALOX15ALDH1A1MAPK1
SCHEMBL6302996 0.90 PARP1 (0.43) PARP1HSD17B10ALOX15ALDH1A1MAPK1
SCHEMBL7713425 0.90 PARP1 (0.44) PARP1HSD17B10ALOX15SMYD3USP2
SCHEMBL7713376 0.90 PARP1 (0.56) PARP1HSD17B10ALOX15ALDH1A1MAPK1
SCHEMBL7708088 0.89 PARP1 (0.47) PARP1HSD17B10ALOX15ALDH1A1MAPK1
SCHEMBL7713340 0.89 PARP1 (0.47) PARP1HSD17B10ALOX15ALDH1A1SMYD3
SCHEMBL7710782 0.88 PARP1 (0.44) PARP1HSD17B10ALOX15ALDH1A1MAPK1
SCHEMBL6308969 0.88 PARP1 (0.46) PARP1HSD17B10ALOX15ALDH1A1MAPK1
SCHEMBL7711139 0.88 PARP1 (0.48) PARP1HSD17B10ALOX15ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed